Related Experiment Videos
Antiangiogenesis therapy for endometriosis
Annemiek W Nap1, Arjan W Griffioen, Gerard A J Dunselman
1Department of Obstetrics and Gynecology, Research Institute for Growth and Development, Maastricht University and University Hospital, 6202 AZ Maastricht, The Netherlands.
The Journal of Clinical Endocrinology and Metabolism
|March 6, 2004
Summary
Angiostatic therapy effectively targets established endometriosis lesions by inhibiting angiogenesis. This approach shows promise for treating endometriosis by reducing lesion growth and microvessel density.
Area of Science:
- Gynecology
- Oncology
- Vascular Biology
Background:
- Angiogenesis is crucial for endometriosis development.
- Current treatments focus on preventing lesion formation, but therapies targeting established lesions are needed.
- Inhibiting angiogenesis may offer a novel therapeutic strategy for endometriosis.
Purpose of the Study:
- To evaluate the efficacy of angiostatic therapy in treating established endometriosis lesions.
- To assess the impact of specific angiostatic compounds on endometriosis growth in a preclinical model.
Main Methods:
- Utilized a nude mouse model of endometriosis.
- Administered angiostatic compounds including anti-human vascular endothelial growth factor, TNP-470, endostatin, and anginex.
- Quantified microvessel density and lesion counts post-treatment.
Main Results:
- Human endometrium exhibits high angiogenic potential, driven by vascular endothelial growth factor-A.
- Angiostatic agents significantly reduced microvessel density and the number of established endometriosis lesions.
- Treatment led to a significant decrease in pericyte-unprotected vessels within remaining lesions.
Conclusions:
- Inhibitors of angiogenesis effectively impede the maintenance and growth of endometriosis.
- Angiostatic agents demonstrate therapeutic potential for endometriosis by targeting neovascularization.
- This study supports the development of angiostatic therapies for managing endometriosis.